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Abstract Irinotecan eluting embolization beads (DEBIRI)
are currently being evaluated in the clinic for the treatment of
colorectal cancer metastases to the liver. The aim of this
study was to determine the safety and pharmacokinetics
associated with two cycles of hepatic embolization using
DEBIRI followed by intravenous administration of irino-
tecan. Pigs were embolized with DEBIRI (100–300 lm,
100 mg dose, n = 6) and blood samples taken over 24 h to
determine plasma levels of irinotecan and SN-38 metabolite
and for haematology and biochemistry. At 24 h an IV infu-
sion of 250 mg/m2 of irinotecan was administered and the
plasma levels taken again. This cycle was repeated 3 weeks
later. A single animal was subjected to a more aggressive
regimen of embolization with 200 mg bead dose and IV of
350 mg/m2 for two cycles. Three animals were sacrificed at
6 weeks and the remaining four (n = 3 standard dose, n = 1
high dose) animals at 12 weeks and detailed histopathology
performed. All animals tolerated the treatments well, with
only minor changes in haematological and biochemical
parameters. There was no overlap in drug plasma levels
observed from the bead and IV treatments when given 24 h
apart and no difference between the pharmacokinetic pro-
files of the two cycles separated by 3 weeks. Irinotecan
plasma AUC values were similar in both the embolization
and IV arms of the study. Cmax values obtained during the IV
arms of the study are approximately double that of the
embolization arms whilst Tmax times are shorter in the IV
arms, supporting extended release of drug from the beads.
Bioavailability for bead-based delivery was double that for
IV administration, which was attributed to reduced clearance
of the drug when delivered by this route. No additive toxicity
was observed as a consequence of the combined treatments.
The combination of irinotecan delivery via drug eluting bead
and IV was well-tolerated with no significant clinical effects.
Pharmacokinetic analyses suggest the bioavailability from
bead-based delivery of drug is double that of IV infusion,
attributable to reduced drug clearance for the former.
Abbreviations
TACE Transarterial chemoembolization
mCRC Colorectal cancer metastases
DEBIRI Drug-eluting beads loaded with irinotecan
1 Introduction
Colorectal cancer is the third leading cause of death from
cancer and the third most common malignancy in both men
(after prostate and lung cancers) and women (after breast
and lung cancers) in the United States. Upon diagnosis,
metastasis of colorectal tumors is common, particularly to
the liver which frequently induces patient death due to
hepatic failure. Treatment options for patients with meta-
static colorectal cancer (mCRC) are limited and clinical
outcome is generally poor. Although surgical resection in
selected patients can achieve 25–45 % 5-year survival, in
all other patient groups it is less than 5 %. Systemic che-
motherapy can palliate symptoms and improve survival
and in recent years the topoisomerase I inhibitor irinotecan,
has been approved for use in combination with 5-FU/
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folinic acid in patients without prior chemotherapy and for
the second-line treatment of this disease as a single agent in
patients who have failed an established 5-FU-containing
treatment regimen [1].
There is increasing interest in local delivery of chemo-
therapy to the liver in an attempt to improve the effectiveness
of these drugs against liver metastases [2]. Transarterial
chemoembolization (TACE) has been used effectively in the
local treatment of hepatocellular carcinoma (HCC) [3, 4] but
in general, it is thought that it is the hypovascular nature of
hepatic mCRC that renders them less suitable for treatment
by conventional TACE [5]. Despite this, Phase II TACE
studies for mCRC have been conducted in a number of
centers, with one study reporting a complete response of
17 % and 1- and 2-year survival rates of 68 and 37 %
respectively using doxorubicin and Lipiodol [6]. Others have
reported a 63 % partial or minor tumor morphologic
response, 62 % of patients with decreased carcinoembryonic
antigen level greater than 50 % and a median survival of
10 months when treated by chemoembolization with 5-flu-
orouracil, mitomycin-C and gelatin sponge [7]. One of the
largest series of patients to be treated to date consisted of 207
patients treated with repeated TACE at 4 week intervals
using mitomycin C with/without gemcitabine and emboli-
zation using lipiodol and degradable starch microspheres [8].
Local tumor control yielded 12 % partial response, 51 %
stable disease and 37 % progressive disease with 1- and
2-year survival rates of 62 and 38 % respectively. The
investigators concluded that TACE is an effective mini-
mally-invasive therapy for neoadjuvant, symptomatic or
palliative treatment of liver metastases in colorectal patients.
DC Bead is an embolization device that has been shown to
load and release drug molecules that carry a positive charge
[9–11]. It has been used combined with doxorubicin in a
number of studies for the treatment of HCC [12–15], chol-
angiocarcinoma [16] and neuroendocrine metastases [17]. It
also has some interaction with certain campothecin ana-
logues such as irinotecan [18] and topotecan hydrochloride
[19, 20]. Preclinical studies have demonstrated that admin-
istration of DEBIRI in a porcine model of hepatic emboli-
zation is safe and results in a reduction of peak plasma drug
levels compared to intrahepatic arterial or intravenous
delivery of a bolus of irinotecan [21, 22]. Moreover, the
beads have been shown to be efficacious in an embolization
model of rat colorectal metastases [23]. Subsequent clinical
evaluation has showed considerable early promise in the
treatment of third line patients [24, 25] or patients refractory
to systemic chemotherapy [26, 27]. Moreover, results from a
small Phase III study showed a statistically significant
improvement in survival (7 months), progression-free sur-
vival (3 months) and quality of life (5 months) for DEBIRI
versus systemic treatment (intravenous FOLFIRI) [28].
These encouraging data have raised interest in treating first
and second-line patients with DEBIRI, but in combination
with other systemic agents to ensure treatment of non-
hepatic disease [29]. The study presented here therefore
aimed to gain information on the pharmacokinetics (PK),
safety and tolerability of a regimen combining DEBIRI with
intravenous (IV) systemic irinotecan in a well-published
porcine model of hepatic arterial embolization. Two treat-
ment cycles were performed, with up to either 100 or 200 mg
of DEBIRI administered with IV irinotecan administered at
either 250 or 350 mg/m2. During each treatment cycle the
DEBIRI administration and the IV irinotecan therapy were
administered on two consecutive days followed by a re-
treatment with the combination therapy 3 weeks later.
2 Materials and methods
2.1 Overview of the study design
This study consisted of three groups of animals as sum-
marized in Table 1 and carried out in accordance to EC
Directive 86/609/EEC for animal experiments. In each
group female domestic large white 9 landrace pigs were
administered 100–300 lm Irinotecan Bead containing
100 mg drug/ml of lyophilized beads (Biocompatibles UK
Ltd, Farnham, UK), via intrahepatic artery injection as a
slow bolus, such that the test material was delivered until
stasis was achieved or the maximum dose had been
administered. This was followed by intravenous infusion of
an irinotecan monotherapy (DBL Irinotecan Concentrate,
Hospira Australia Pty Ltd, Mulgrave, Australia) over
30–90 min, 24 h post embolization. Each animal under-
went two cycles of each treatment before necropsy of the
group 1 animals at 6 weeks after initial embolization. The
remaining four animals in groups 2 and 3 underwent nec-
ropsy 12 weeks after initial embolization.
In group 1 and 2, the DEBIRI was administered up to a
maximum of 100 mg irinotecan dose (using up to 1 ml of
beads containing 100 mg irinotecan). Each vial of the beads
was mixed with water for injection and contrast medium to a
final volume of up to 10 ml. Irinotecan monotherapy was
administered as an intravenous infusion of 250 mg/m2 dose
over 30–90 min. The dose calculations for the irinotecan
followed those in the literature [30], using the formula:
Surface area ¼ 0:0734  weight0:656  dose required
The solution was withdrawn from the vial and diluted in
0.9 % sodium chloride injection, BP, prior to infusion to a
final concentration range of 0.12–2.8 mg/ml.
It was unknown at the time whether the animals would
tolerate an escalated dosing regimen and hence just one
animal was treated with higher drug concentrations (group
3). In this case, DEBIRI was administered up to a maximum
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of 200 mg irinotecan dose (using up to 2 ml of beads). Each
vial of the beads was mixed with water for injection and
contrast medium to a final volume of up to 10 ml. The iri-
notecan monotherapy was also escalated and administered as
an intravenous infusion of 350 mg/m2 dose over 30–90 min.
Angiography was performed and recorded prior to,
during and following DEBIRI administrations for verifi-
cation of place location. At protocol-specified time points,
clinical and vascular access site observations were per-
formed, body weights were recorded, and blood samples
were collected for evaluation of clinical pathology
parameters. Additional blood samples were collected for
quantification of irinotecan (CPT-11) and the metabolite
SN-38. On day 42 (±1 day), the group 1 animals were
humanely killed (or died) and subjected to a comprehen-
sive necropsy. Samples were collected for histological
assessment. On day 84 the remaining animals in groups 2
and 3 underwent these assessments.
2.2 Interventional procedures
A cutdown procedure was used to isolate the jugular vein
and two PVC catheters, with silastic tubing placed over the
section of the catheter immediately proximal to the entry
point, were inserted into the vein. Once the catheters were
in the final position and had been checked to ensure that
they were flowing well, they were sutured to surrounding
muscle to stabilize the catheters in situ. The catheters were
sutured to the skin (exposed) around the neck. The access
site was sutured closed around the external region of the
catheter. A zip-lock bag was sutured to the back of the
animal and used to hold the catheters when not in use. One
catheter was used for blood sampling, the other was used
for the IV administration of irinotecan. The catheters
remained in place up to 48 h post-infusion, after which
they were removed. Subsequent blood samples were
obtained by venepuncture of an appropriate vessel.
The femoral artery was accessed and an appropriately
sized guidewire followed by an introducer ‘‘portal entry’’
then a 4F guide catheter were advanced into the common
hepatic artery. The catheter was passed over the guidewire
into the left liver lobe and the guidewire was subsequently
removed. Angiography was performed to confirm the
catheter position in the target region. With the catheter in
position, up to 2 ml of DEBIRI (in a total volume of up to
20 ml) were slowly administered, at a rate to minimize
reflux from the target area. The total volume administered
was recorded (Table 2). A final angiogram was performed
5 min after delivery of the microspheres was completed.
After the final angiogram, the catheter and introducer
sheath were removed from the animals. The femoral artery
was ligated or pressure applied to the access site until
haemostasis was obtained and the site then sutured closed.
Output angiograms were used to qualitatively assess the
extent of embolization. The angiograms were taken prior to
embolization, during embolization and 5 min post-embo-
lization. Where complete embolization was judged to have
occurred, the artery antegrade to the tip of the catheter
displayed as a blind vessel with essentially no flow,
although some contrast was present still in the lobe. Scores
were graded by comparing the speed of antegrade flow
within the liver compared to the speed of antegrade flow
within non-embolized vessels. Reflux of contrast media in
a retrograde direction after injection was also considered
when assessing embolization. Vascular flow was thus
graded from zero (complete occlusion) to three (no
occlusion).
The intravenous administration of irinotecan was per-
formed on conscious animals. The infusion was adminis-
tered via a previously placed jugular catheter. The drip rate
was set to approximately 160 drops/min. The animals
received the appropriate volume of irinotecan in 500 ml of
sterile 0.9 % saline. Heart rate (HR), oxygen saturation and
other parameters were measured by pulse oximetry.
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Individual dose administration data and extent of
embolization are presented in Table 2. DEBIRI was
administered to the left lobe of the liver. All animals in
groups 1 and 2 received their full dose of DEBIRI
(100 mg) on both occasions. The group 3 pig received the
full 200 mg at the primary embolization, but only 135 mg
on the secondary embolization due to stasis being achieved
at that point. Table 3 shows the amount of irinotecan
administered intravenously on the two occasions. All ani-
mals received their full dose of irinotecan. There were
instances of frothing at the mouth or coughing in all pigs.
2.3 Blood sample collection and processing
Blood samples for hematological and biochemical analyses
were collected prior to embolization (baseline), and on days
2, 3, 7, 14, 22 (prior to embolization), 23, 24, 28, 42, 63 and
84 (all collections after day 3 are ± 2 days). Samples for
pharmacokinetic analyses were collected prior to emboli-
zation (baseline), immediately on completion of emboliza-
tion (0 time, post-embolization) and at 2, 5, 10, 15, 30, 60,
90 min, 2, 3, 4, 6, 9, 12, 16, 20 h following completion of
embolization; and prior to IV infusion (24 h post-emboli-
zation), 2, 5, 10, 15, 30, 60, 90 min, 2, 3, 4, 6, 9, 12, 16, 20, 24
and 48 h post-infusion. For haematology measurements,
blood samples were collected into tubes containing tri-
potassium (K3)EDTA and were analysed for the laboratory
standard complete blood examination (CBE) parameters
using a SYSMEX-XE-2100 (TOA Medical Electronics,
Kobe, Japan) hematology analyzer. A blood film was ana-
lyzed for the white cell differential and any abnormal cells.
For biochemistry measurements, blood samples were col-
lected into tubes containing a clot activator and were pro-
cessed for serum. The standard multiple biochemical
analysis (MBA) parameters and lipid screen were deter-
mined using an Olympus AU5400 (Olympus America Inc,
NY, USA) chemistry analyzer. Whole blood samples for
pharmacokinetics bioanalysis were collected into tubes
containing lithium heparin, centrifuged for 5 min at
3000 rpm and the plasma was extracted. The plasma was
immediately stored at -20 C. The frozen plasma samples
were analyzed for irinotecan and the metabolite SN-38 using
a validated HPLC method (Shimadzu Corporation, Kyoto,
Japan).
2.4 Necropsy, tissue collection and histopathology
All pigs were subjected to a comprehensive necropsy, and
any macroscopic abnormalities were noted. Sections of liver
(site of embolization and non-embolized liver tissue), duo-
denum, jejunum, ileum, colon, caecum, stomach, kidneys,
gall bladder, spleen, lung, heart and brain were dissected free
and fixed in 10 % neutral buffered formalin. Tissue samples
collected on day 42 ± 1, and day 84 ± 1, were trimmed,
Table 2 DEBIRI dose
administered and extent of
embolization
















1 100 N 1 100 N 2 2 Close to stasis
1 100 Y 0 100 N 1 2
1 100 Y 0 100 Y 0 – No score—died
2 100 N 1 100 N 2 2
2 100 N 1 100 N 2 2
2 100 N 2 100 N 2 2
3 200 Y 0 135 Y 0 1 Not all beads in
Table 3 Doses of IV irinotecan
administered















1 250 31.0 174.6 8.7 37.5 197.8 9.9
1 250 31.0 174.6 8.7 40.0 206.3 10.3
1 250 30.0 170.9 8.5 36.5 194.3 9.7
2 250 32.0 178.2 8.9 45.5 224.5 11.2
2 250 33.5 183.7 9.2 43.5 218.0 10.9
2 250 32.5 180.1 9.0 39.5 204.6 10.2
3 350 30.5 241.8 12.1 38.5 281.7 14.1
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embedded, and sectioned. The slides were stained with
hematoxylin and eosin.
2.5 Pharmacokinetics
The following parameters were derived or calculated where
possible for both CPT-11 and SN-38; area under the con-
centration–time curve (AUC), half-life, Tmax, and Cmax.
The Tmax and Cmax values were obtained by visual exam-
ination of the data. The AUC values were calculated using
the trapezoid rule by GraphPad Prism 4 (GraphPad Soft-
ware Inc, CA, USA). The terminal elimination half-life
(t1/2) was determined by linear regression of the terminal
log-concentration data points after plotting the plasma
concentrations against time, using the formula:
T1=2 ¼ 0:693
b
where b = slope 9 (–2.303).
In order to make estimates of clearance and bioavail-
ability of the drug, the AUCs were extrapolated to infinite
time and then normalized to 174 mg dose (equivalent to
250 mg/m2 dose in a nominal typical animal), giving
nAUC0-inf. The bioavailability (F) was calculated as the
ratio of the nAUC0-inf values for bead-based to IV delivery
routes. Clearance was calculated as the absolute dose
administered divided by AUC0-inf, resulting in systemic
clearance (CL) for IV and apparent clearance (CL/F) for
bead-based delivery. All PK parameters in the text are
reported as mean ± standard deviations (SD).
3 Results
3.1 Body weight
Changes in body weights are shown in Fig. 1. Body
weights at the time of the initial intervention ranged from
30.0 to 33.5 kg. Body weight increased in all animals over
the duration of the study, although one animal (pig 3) did
not show the same degree of increase as the others, was
moribund on day 41, and died during the final angiogram.
This was a consequence of a generalized infection and was
not treatment-related.
3.2 Hematology
The data for groups 1 and 2 up to day 42 were compared to
the baseline (pre-embolization) values. The group 3 animal
was excluded from these analyses. The only statistically
significant changes from baseline were in the platelet counts
at days 2 (P \ 0.001), 3 (P \ 0.001), 23 (P \ 0.01), 24
(P \ 0.001) and 28 (P \ 0.01) and 42 (P \ 0.001). On each
occasion, the values were lower than the initial mean platelet
count. There was a wide variation in platelet counts between
the pigs (see Fig. 2), with only one animal having platelet
counts outside the reference interval ([550 9 109/l). The
data for the group 2 animals at days 63 and 84 were also
compared to baseline. Again, the only significant differences
were in the platelet counts (P \ 0.01 on both days).
Eosinophil counts increased in all animals except one on
day 23, and remained high on day 24 in five animals. The
eosinophils were also increased from baseline on days 2 or
3 in three animals. There was a transient increase in the
mean (n = 7) neutrophil and eosinophil counts in the 48 h
following treatments, which returned to baseline. These are
shown in Fig. 2. There was no evidence of neutropaenia,
which has been reported in human studies of various dos-
ing regimens [31].
3.3 Biochemistry
The data for the group 1 and 2 animals up to day 42 were
compared to the baseline (pre-embolization) values. The
only statistically significant differences from baseline were
on day 2 (LDH increased, P \ 0.001); day 3 (LDH
increased, P \ 0.05); day 7 (ALP decreased, P \ 0.05); day
14 (LDH increased, P \ 0.001); day 23 (LDH increased,
P \ 0.001). The data for the group 2 animals for days 63 and
84 were also compared to baseline. Again, the only signifi-
cant differences were in the LDH (P \ 0.0001) on day 63.
Following treatments, there were increases in mean (n = 7)
serum total and ionised calcium levels, and decreases in
serum phosphate (Fig. 2). The elevated serum calcium
concentrations were not observed in a previously reported
study where the pigs only had one intervention [21]. These
findings were considered not clinically significant. Changes



























Group 2 & 3
Necropsy
Fig. 1 Body weight of pigs over the experimental period (note:
animals were non fasted on days 35, 49, 56, 70 and 77. All other
weights are of fasted animals)
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increase following treatments (Fig. 2). There was a slight
decrease in the mean serum albumin concentrations (n = 7)
following the initial treatments (still within reference
interval to day 22), and these remained decreased to day 28
(below reference interval). The total protein concentrations
were within the reference interval throughout.
3.4 Plasma pharmacokinetics
All pre-embolization samples were less than the lower limit
of quantification (LOQ) for both analytes. Figure 3 depicts
the average irinotecan plasma profiles for following
DEBIRI and IV irinotecan administration in groups 1 and
2. The overall profiles for the two cycles appear similar,
and following bead delivery, the levels of the drug in the
plasma drop below the LOQ before the IV dose is given.
Figure 4 shows the actual irinotecan levels for each cycle
(Fig. 4a, error bars removed for clarity) with the same data
in which the concentrations have been dose-normalized for
comparative purposes (Fig. 4b) and the same graphs for
SN-38 (Fig. 4c, d). Clearly, from Fig. 4b the dose-nor-
malized AUC values for the bead-based delivery are sub-
stantially higher than for IV delivery (from Table 4,
12821.7 and 11838.9 ng h/ml for the primary and sec-
ondary bead delivery versus 6330.8 and 5427.6 ng h/ml for
the primary and secondary IV delivery). This results in a
bioavailability (F) for bead-based delivery of 206 and
220 % for the primary and secondary interventions
respectively. As it is not possible to deliver more dose than
that administered, this increase in F is attributed to a
reduced clearance for bead-based delivery of irinotecan
(Table 4). Figure 4e shows the irinotecan plasma levels for
the group 3 animal with escalated dose. This figure also
includes the curve of the primary embolization with
DEBIRI at 100 mg dose to allow comparison between 200,
135 and 100 mg DEBIRI doses. Although these curves
have not been dose-normalized, it is clear the significant
impact the increased dose has on the AUC.
The mean PK data (±SD) for irinotecan and SN-38
measured in each phase of the study for groups 1 and 2 are
shown in Table 5. Data from the group 3 animal are
omitted from the tables due to the higher dose of irinotecan
that was given to this pig. The terminal elimination half-
life values for SN-38 were not calculated for some profiles
due to insufficient or non-conforming data. In general, SN-
38 plasma concentrations were very low (about 1,000 times
lower than irinotecan) and were either just above or below
quantification limits in most cases.
Initial inspection of the IV data indicates clear 2-com-
partment pharmacokinetics, demonstrated as an initial
rapid first order (i.e. linear on a log scale) decline in con-
centrations until approximately 500–750 min, presumably
due to distribution of irinotecan out of the blood into tis-
sues (the ‘‘distribution phase’’). This is then followed by a
slower ‘‘terminal’’ phase, presumably due to elimination of
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Fig. 2 Hematological and biochemical parameters (?SD, n = 7,
1–42 days; n = 4, 43–48 days): a Mean platelets; instances of
clumped platelets have been excluded. b Mean neutrophil and
eosinophil % of total white cell counts. c Mean phosphate, total
calcium and ionized calcium (calculated). d Mean concentrations of
gamma glutamyltransferase (GGT), alkaline phosphatase (ALP),
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST). e Mean serum albumin concentration
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900 min onwards. Examination of the DEBIRI curves
reveals a slightly more complex plasma profile, for which
there is a tendency for an initial decline in levels during the
first minutes, followed by a small plateau or elevation for a
few hours and subsequently a slower decline from thereon
(best seen in Fig. 4e for the primary embolization using the
200 mg dose). After some hours there becomes a much
slower mono-exponential (1-compartment) decline. This
also appears to be much slower than the initial distribution-
phase decline in concentrations in comparison to the IV
data but closer inspection reveals some evidence that there
may be a second slower phase which occurs at the very end
of the study.
3.5 Histopathology
Microscopically, in the liver of all pigs, morphological
changes resulting from bead injection were principally
characterized by a necrotizing vasculopathy in portal
arteries, and a granulomatous inflammatory reaction sur-
rounding the beads, with substantial portal fibrosis and
inflammatory infiltration. This is typical of what has been
previously reported [21]. A variable number of beads were
found in hepatic portal tracts, ranging from one to up to ten
(Fig. 5a), which is a factor of the vessel size. Beads were
frequently found in the lumina of degenerate blood vessels,
often surrounded by a granulomatous reaction of epitheli-
oid macrophages and multinucleated giant cells (consistent
with the expected foreign body response), (Fig. 5b), or
occasionally in the lumen of bile ducts (Fig. 5c).
There were many similarities between the hepatic
pathology in the groups 2 and 3 pigs at 84 days and the
group 1 pigs at 42 days. Hepatic arteries containing beads
in the portal region showed a necrotising vasculopathy,
often surrounded by a granulomatous reaction or concen-
tric fibrosis. There was marked periportal fibrosis with
encroachment upon, and replacement of, contiguous
hepatocytes and a generally mild mononuclear cell infil-
trate sometimes with a few eosinophils. On occasion in
two animals there was marked bile ductule hyperplasia.
Lymphoid nodules were occasionally found in the portal
region and a few blood vessels sometimes showed marked
smooth muscle hypertrophy. In many livers, there was
mild, multifocal hepatocyte necrosis with a mononuclear
cell reaction, including Kupffer cells. Thrombi in hepatic
vessels were not found, except in the group 3 pig in the left
lateral lobe, which produced an infarct. There was an
occasional bead found in a bile duct lumen and in gastric
and duodenal walls, while beads were frequently found in
mesenteric blood vessels of the porta hepatis. These find-
ings were more common in the group 3 pig that had
received the largest volume of beads. The main histolog-
ical differences between this study and that previously
reported [21] were the higher frequency of lymphatic
dilatation in the current study, and the reduced incidence
of hepatic vessel thrombi, with the exception of the group
3 pig which received the higher dose and hence volume of
beads.
While the hepatic arteries containing beads were usually
recognisable as blood vessels, lumina were markedly
dilated and walls invariably attenuated and generally rep-
resented by a narrow band containing pyknotic myocyte
and endothelial nuclei. Affected vessels were surrounded,
to varying degrees, by a granulomatous inflammatory
reaction and fibroplasia. This total or subtotal destruction
of vessel walls, putatively due to pressure atrophy from
intraluminal beads, was designated a necrotizing vascu-
lopathy (Fig. 5d). Periportal fibrosis (Fig. 5c) was usually
moderate to severe with encroachment upon, and con-
comitant loss of, surrounding hepatic parenchyma and
there was invariably an inflammatory infiltrate comprised








































Fig. 3 Plasma level profiles of irinotecan from both cycles of bead-based and IV delivery, demonstrating no overlap of systemic drug from the
two treatments in either cycle
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In order to analyze the lobar distribution of injected
beads, lobes were blind coded for histopathological
examination and six sections of approximately equal size
randomly selected from each lobe. The number of beads in
each section was then counted and summed for each lobe.
In all pigs beads were preferentially located in the left
hepatic lobes (lateral and central) although for one pig in
group 1, numerous beads were also found in the right lat-
eral lobe, indicating an off-target delivery. In the group 3
pig, there were more beads in the caudate lobe than for any
of the other pigs, a result of the increased volume admin-
istered. The number of beads found in other lobes was
small.
4 Discussion
The treatment options for metastatic colorectal cancer to
the liver have broadened in recent years, with the advent of
more effective agents such as irinotecan and oxaliplatin
resulting in an increase in median survival from 6- to over
20 months [32]. The combination of irinotecan with bolus
5-fluoruracil and leucovorin (IFL) with bevacizumab (an
antibody that targets vascular endothelial growth factor)
offers further advantage as a first line therapy [33]; whilst
irinotecan-refractory patients show improved response and
longer median time to progression when combined with
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Fig. 4 Plasma level profiles for primary and secondary cycles:
a irinotecan 100 mg DEB and 250 mg/m2 IV; b irinotecan 100 mg
DEB and 250 mg/m2 IV normalized for dose; c SN-38 100 mg DEB
and 250 mg/m2 IV; d SN-38 100 mg DEB and 250 mg/m2 IV
normalized for dose; e irinotecan 100 mg and 200 mg DEB and
350 mg/m2 IV
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receptor [34]. All of these treatments however, have
associated dose-limiting toxicity, with frequent mucositis,
nausea and vomiting, alopecia and in some cases severe
diarrhea. Local therapy of colorectal metastases to the liver
using DEBIRI in third-line patients has resulted in reported
reductions in some of these side-effects [24]. There is
therefore mounting interest in combining systemic and
local-based therapy of tumours, one aim being to attempt
to reduce the total systemic drug load and hence limit
toxicity. Moreover, tumor spread can be controlled via
the combined embolic effect and local delivery of
chemotherapy attained using drug eluting beads. This type
of multi-modal therapy could potentially present issues
with overlapping toxicities or prolonged and/or cumulative
effects that have not been previously observed in vivo. This
preclinical study was therefore designed to test the feasi-
bility of performing TACE with DEBIRI followed by IV
irinotecan at clinically-relevant doses, to monitor the safety
of the procedure and examine the pharmacokinetics of the
drug from the two different routes of administration.
In terms of the effect of the combined procedure on
the liver function of the animals, statistically significant
Table 4 Pharmacokinetic parameters for irinotecan delivery
Phase Parameter Average SD CV (%) Units
1 Embolization Dose 100 0 0 mg
k 0.219 0.026 12.09 /h
AUC0-t 7307.10 2129.28 29.14 ng h/ml
nAUC0-inf 12821.72 3714.94 28.97 ng h/ml
CL/F 240.22 60.38 25.13 ml/min
F 205.54 18.72 9.11 %
2 Embolization Dose 100 0 0 mg
k 0.204 0.038 18.62 /h
AUC0-t 6724.38 2351.96 34.98 ng h/ml
nAUC0-inf 11838.92 4130.29 34.89 ng h/ml
CL/F 266.41 75.94 28.51 ml/min
F 219.06 22.85 10.43 %
1 IV Dose 177.02 4.58 2.58 mg
k 0.112 0.016 14.04 /h
AUC0-t 6345.13 2374.00 37.41 ng h/ml
nAUC0-inf 6330.76 2264.09 35.76 ng h/ml
CL 494.76 127.70 25.81 ml/min
2 IV Dose 207.58 11.64 5.61 mg
k 0.143 0.044 30.54 /h
AUC0-t 6309.65 2047.31 32.45 ng h/ml
nAUC0-inf 5427.57 1909.68 35.18 ng h/ml
CL 580.44 162.27 27.96 ml/min
Table 5 Key pharmacokinetic data
Phase AUC (ng/ml h) T (h) Cmax (ng/ml) Tmax (min)
Irinotecan
1 Embolization 7307 ± 2129 3.2 ± 0.4 1493 ± 432 10.0 ± 4.5
2 Embolization 6724 ± 2352 3.5 ± 0.8 1571 ± 396 6.2 ± 4.5
1 IV 6345 ± 2374 6.3 ± 0.9 2837 ± 709 0.7 ± 1.0
2 IV 6310 ± 2047 5.4 ± 2.0 3302 ± 840 0.7 ± 1.0
SN-38
1 Embolization 5.5 ± 3.6 5.0 ± 3.6 1.7 ± 0.9 26.0 ± 20.4
2 Embolization 5.9 ± 2.9 5.9 ± 2.9 1.9 ± 0.2 43.3 ± 45.8
1 IV 5.0 ± 2.1 2.0 ± 0.5 3.5 ± 0.8 1.2 ± 2.0
2 IV 4.4 ± 2.0 2.2 ± 0.3 3.1 ± 0.5 1.0 ± 1.1
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changes from baseline in clinical pathology (hematology
and serum chemistry) were seen only in platelet counts,
LDH and ALP. It has been previously observed however,
in human studies involving hepatic TACE, that it is not
unusual for many liver enzyme levels to be elevated five to
20-fold post-procedure [35, 36]. In this context, the chan-
ges seen here are minor and unlikely to be of concern with
respect to clinical translation.
Irinotecan plasma AUC values are very similar in both the
embolization and IV arms of the study. Allowing for dose-
normalization, the bioavailability for bead-based delivery
increases to an average of 210 %, attributable to a decreased
drug clearance for this route of administration. Hepatic
clearance is determined by liver blood flow, intrinistic
metabolic clearance and the unbound fraction of drug in
blood. It is likely all three factors contribute to the reduced
clearance, but in particular the first two mechanisms, as the
embolic beads will obstruct arterial blood flow and local
delivery of high concentrations of drug into the liver
parenchyma could potentially saturate enzymes responsible
for the drug’s metabolism. Cmax values obtained during the
IV arms of the study are approximately double that of the
embolization arms, whilst Tmax times are shorter, both sup-
porting the premise of slower release of the drug from the
beads compared to the IV infusion. This study did not
determine the form of the irinotecan, as it is known to exist in
its active lactone and less active carboxylate forms, the ratio
of which is determined by a pH driven equilibrium. It has
been demonstrated however, that it is the active lactone form
of the drug which exists within the beads and which is
continually eluted at the site of delivery [37].
The shape of the PK plasma profiles for the IV and bead
administrations differ significantly. If attempts are made to
model the bead PK profile, the most appropriate fit to the
data assumes an immediate bolus of drug followed by a
much slower infusion over the ensuing hours; this leads to
slightly elevated plasma levels of drug and metabolite
during this phase in comparison to IV administration when
normalized (Fig. 4c, d). This initial burst of drug can be
rationalized, as depending upon the type of contrast agent
used to suspend the beads and visualize delivery, some
5–15 % of the loaded irinotecan dose can be displaced into
the suspension medium upon mixing and hence would
effectively provide an immediate intra-arterial bolus. This
is then followed by the slower release phase of drug elution
from the beads, which may give rise to a ‘bump’ in the PK
profile when the rate of infusion is close to or faster than
the rate of clearance.
T appears longer in the IV arms compared to the












Fig. 5 Selected histopathology: a numerous beads in a hepatic artery;
b bead (B) surrounded by a granulamatous inflammatory reaction of
epithelioid macrophages and multinucleated giant cells (G), inter-
spersed with eosinophils; c bead in the lumen of a bile duct (BD);
there is also marked periportal fibrosis (PF); d beads in hepatic
arteries with marked attenuation of the vessel wall (arrow) (necro-
tizing vasculopathy) and early granulomatous response (G)
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given the evidence for reduced clearance of drug after
bead-based delivery, which should yield a longer T. The
apparent mono-exponential (1-compartment) decline of
drug after bead-based delivery is slower than the initial
distribution-phase decline for IV but there is evidence for a
second slower phase occurring at the end of the sampling
period (between 900 and 1,500 min), seen as a change in
slope of the decline. This is most probably the consequence
of ‘‘flip-flop’’ kinetics typically observed for sustained
release systems, in which the absorption rate (i.e. com-
posite of the release of irinotecan from the beads, diffusion
through tissue and its subsequent appearance in the blood)
becomes rate-limiting over the elimination process [38].
SN-38 plasma AUC values are approximately 1,000-
fold less than those obtained for irinotecan. SN-38 plasma
AUC values are similar in both the embolization and IV
arms of the study. Cmax values do appear to be higher,
and Tmax values shorter, during the IV arm of the study
than those obtained from the embolization arm but again,
dose-normalization suggests the bead-based delivery may
afford a longer phase of low-levels SN-38 exposure. This
could be advantageous, as there are reports in the litera-
ture that prolonged exposure to low levels of SN-38
afford greater anti-tumor activity [39]. SN-38 has been
implicated in the appearance of late-onset diarrhea, which
is difficult to treat and is thought to be associated with
SN-38-induced GI mucosal toxicity [40]. Interestingly, in
studies performed to date with DEBIRI, no significant
side effects related to diarrhea have been reported [24, 25,
41, 42].
From a pharmacokinetic stand-point there appears to be
no difference between the primary and secondary phases of
the study, other than for the group 3 animal, the entire
200 mg dose could not be administered in the second cycle
and hence the plasma levels were correspondingly lower.
At 24 h post embolization for both cycles of treatment, the
drug had clearly dropped below the LOQ and there was
therefore no overlap in the plasma levels with the IV
administration and hence risk of over-dosing due to over-
lapping toxicities.
At necropsy, one animal had a generalized infection
with tissue changes (unrelated to treatment regimen), and
another animal had an area of pallor in the left lateral liver
lobe (an infarct due to arterial thrombosis). Microscopi-
cally, in the liver of all pigs, morphological changes
resulting from bead injection were principally character-
ized by a necrotizing vasculopathy in portal arteries, and a
granulomatous inflammatory reaction surrounding the
beads, with substantial portal fibrosis and inflammatory
infiltration. These observations were the same as those
typically observed in the same animal model, in which
animals were treated with DEBIRI on their own [21]. The
more aggressive treatment regimen followed in this study
also largely compared to that previously reported, resulting
in only minor differences between the two. In the current
study there was an increase in serum calcium concentra-
tions not seen in the previous study. Histologically, there
was a higher frequency of lymphatic dilatation in the cur-
rent study compared to previously, but a reduced incidence
of hepatic vessel thrombi, with the exception of the group 3
pig which received the higher dose. Overall, there were no
findings that would suggest any undue additive toxicity was
experienced by combining bead-based therapy with IV
delivery of irinotecan.
5 Conclusion
Embolization using a 100 mg dose of DEBIRI, followed by
IV administration 24 h later at 250 mg/m2 was a well-
tolerated treatment regimen, with only minor changes in
hematological and biochemical parameters which were not
clinically significant. The more aggressive treatment regi-
men of the group 3 animal showed similar results to those
in groups 1 and 2, with no apparent additional toxicity
which suggests the use of even higher doses could be
possible.
There was evidence that the bioavailability of irinotecan
from hepatically implanted beads in the pig is an average
of 200–220 %. This apparent doubling of the systemic
availability is a physical manifestation of the reduced
systemic clearance of the drug. This is both a consequence
of the primary mode of action of the embolic device to
reduce hepatic blood flow and to a decrease in the intrinsic
metabolism of the drug due to local delivery from the
device. The clinical importance of these unique pharma-
cokinetic aspects of bead-based delivery may be that
(i) similar systemic exposure to irinotecan is possible using
doses that are approximately 50 % smaller than IV
administration, (ii) potentially greater localized exposure
of the liver may be obtained which may afford a greater
effect on hepatic tumors.
This study therefore indicates it is feasible to undertake
a combination of systemic and bead-based delivery of iri-
notecan without fear of over-dosing the systemic circula-
tion as long as the embolization and IV infusion are
separated by at least a 24 h period. Liver function and
histopathological changes are not significantly affected
over that seen for embolization alone. Further studies are
on-going to provide further valuable insight into the
potential of this novel method of treatment of colorectal
metastases to the liver.
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